Compare · JNJ vs SYRE
JNJ vs SYRE
Side-by-side comparison of Johnson & Johnson (JNJ) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $573.71B, about 81.8x SYRE ($7.01B).
- Over the past year, JNJ is up 53.5% and SYRE is up 349.6% - SYRE leads by 296.1 points.
- SYRE has been more active in the news (15 items in the past 4 weeks vs 12 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- Johnson & Johnson
- Spyre Therapeutics Inc.
- Price
- $238.31-0.09%
- $80.77+7.62%
- Market cap
- $573.71B
- $7.01B
- 1M return
- +6.23%
- +7.56%
- 1Y return
- +53.52%
- +349.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 12
- 15
- Recent ratings
- 25
- 10
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Latest SYRE
- Spyre Therapeutics Announces Grants of Inducement Awards
- Chief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)
- Chief Financial Officer Burrows Scott L sold $532,937 worth of shares (7,500 units at $71.06) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $14.50 (SEC Form 4)
- Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
- Spyre Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- SEC Form 4 filed by Director Albers Jeffrey W.
- SEC Form 4 filed by Director Henderson Michael Thomas
- SEC Form 4 filed by Director Stelzer Laurie